Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.

IF 1.6 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2025-09-08 DOI:10.1111/ajco.70012

Takashi Matsuki, Takuro Okada, Chihiro Fushimi, Hideaki Takahashi, Isaku Okamoto, Takahito Kondo, Kunihiko Tokashiki, Kenji Hanyu, Takuma Kishida, Tatsuya Ito, Gai Yamashita, Kiyoaki Tsukahara, Tatsuo Masubuchi, Yuichiro Tada, Kaho Momiyama, Yukiko Asako, Kohei Hagiwara, Hidetaka Ikemiyagi, Ryohei Yaguchi, Nobuhiko Oridate, Go Omura, Taku Yamashita

{"title":"Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.","authors":"Takashi Matsuki, Takuro Okada, Chihiro Fushimi, Hideaki Takahashi, Isaku Okamoto, Takahito Kondo, Kunihiko Tokashiki, Kenji Hanyu, Takuma Kishida, Tatsuya Ito, Gai Yamashita, Kiyoaki Tsukahara, Tatsuo Masubuchi, Yuichiro Tada, Kaho Momiyama, Yukiko Asako, Kohei Hagiwara, Hidetaka Ikemiyagi, Ryohei Yaguchi, Nobuhiko Oridate, Go Omura, Taku Yamashita","doi":"10.1111/ajco.70012","DOIUrl":null,"url":null,"abstract":"Background: In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development of immune-related adverse events (irAEs) remains unclear.Methods: We conducted a multicenter retrospective cohort study to evaluate whether pre-treatment hematological markers-including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and the CRP-albumin-lymphocyte (CALLY) index-predict the development of irAEs in 147 patients with R/M SCCHN treated with pembrolizumab.Results: Lower NLR and PLR, as well as higher LMR and CALLY index, were significantly associated with a higher incidence of irAEs. Furthermore, NLR and LMR were significantly correlated with the occurrence of severe (Grade ≥ 3) irAEs.Conclusion: Pre-treatment NLR, PLR, LMR, and CALLY index may serve as useful predictive markers for the development of irAEs in patients with R/M SCCHN treated with pembrolizumab.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70012","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development of immune-related adverse events (irAEs) remains unclear.

Methods: We conducted a multicenter retrospective cohort study to evaluate whether pre-treatment hematological markers-including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and the CRP-albumin-lymphocyte (CALLY) index-predict the development of irAEs in 147 patients with R/M SCCHN treated with pembrolizumab.

Results: Lower NLR and PLR, as well as higher LMR and CALLY index, were significantly associated with a higher incidence of irAEs. Furthermore, NLR and LMR were significantly correlated with the occurrence of severe (Grade ≥ 3) irAEs.

Conclusion: Pre-treatment NLR, PLR, LMR, and CALLY index may serve as useful predictive markers for the development of irAEs in patients with R/M SCCHN treated with pembrolizumab.

查看原文本刊更多论文

血液标志物预测使用派姆单抗治疗的头颈部复发或转移性鳞状细胞癌患者的免疫相关不良事件

背景：在头颈部复发或转移性鳞状细胞癌（R/M SCCHN）患者中，血液学指标与治疗结果之间的相关性已经建立。然而，它们在免疫相关不良事件（irAEs）发生中的预测作用尚不清楚。方法：我们进行了一项多中心回顾性队列研究，以评估治疗前血液标志物（包括中性粒细胞与淋巴细胞比率（NLR）、血小板与淋巴细胞比率（PLR）、淋巴细胞与单核细胞比率（LMR）和crp -白蛋白淋巴细胞（CALLY）指数）是否能预测147例接受派姆单抗治疗的R/M SCCHN患者的irae发展。结果：较低的NLR和PLR以及较高的LMR和CALLY指数与较高的irae发生率显著相关。此外，NLR和LMR与严重（≥3级）irae的发生显著相关。结论：治疗前NLR、PLR、LMR和CALLY指数可作为派姆单抗治疗的R/M SCCHN患者发生irae的有用预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.